Thank you for donating!

You can donate using the following services.

How do you want to hear from us?

How do you want to hear from NPUK?

Even if you have previously told us how you would like to hear from us and/or you have supported us for many years, new data protection legislation requires you to provide your explicit consent in order for us to continue to contact you in the ways that are important to you.

Please use this form to tell us your preferences. You can also change your mind at any time – you will find further details about how to do this below. In the future, we will only contact you about the areas of our work you choose via the communication methods you prefer. Please complete all fields.

I would like to receive information about NPUK services, NPUK events, information and updates regarding the work of the Charity, including the NPUK Newsletter, in the following ways:

I would like to interact with the NPUK Care and Support Team, including the Clinical Nurse Specialist, Senior Families Advocate, Project Families Officer or Central Office Team. I give my consent for them to contact me in the following ways:

I would like to receive information and updates regarding research, clinical trials, treatment and care options relevant to Niemann-Pick disease, in the following ways:

I would like to receive information about NPUK Fundraising events and activities in the following ways:

I do not wish to hear from NPUK:

Your details

First name(s)

Surname

Address Line 1

Address Line 2

Address Line 3

Postcode

Country

Telephone - landline (include dialling code)

Telephone - mobile (include dialling code)

What is your connection to NPUK?

Email

If you're under 16

Your age

Date of birth

Parent/guardian contact email

Parent/guardian contact telephone (include dailing code)

Do you have any additional comments?

Your Details Are Safe With Us – Privacy Statement:

We will always store your personal details securely. We will only use them to provide the service(s) that you have requested and communicate with you in the way(s) you have agreed to. Your details may also be used for analysis purposes, to help us provide the best possible service. We will not pass on your details to anyone else and we will only share them if required to do so by law.

Latest news

15.03.19

CTD Holdings Announces Plan to Launch Clinical Trial of Trappsol® Cyclo™ in Alzheimer’s Disease

ALACHUA, FL – (Globe Newswire) – March 14, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical trial for treatment of Alzheimer’s Disease. The trial will use Trappsol® Cyclo™, the company’s proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously.

Read more

11.03.19

IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC)

IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC): OXFORD, UK, March 11, 2019-- IntraBio Inc., a late-stage biopharmaceutical company, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its Clinical Trial Authorisation (CTA) Application for Clinical Trial IB1001-201 with its lead compound (IB1001) for the treatment of Niemann-Pick disease Type C (NPC).

Read more
View all news Subscribe